Testosterone therapy linked to sharply higher cardiovascular risk in postmenopausal women
Start here
A retrospective cohort study from a Drexel University team, using data from the TriNetX US Collaborative Network, examined more than 6,300 propensity score-matched postmenopausal women and found that testosterone therapy was significantly associated with a composite cardiovascular disease risk, with a hazard ratio of 8.08 (95% CI 4.72-13.82). Absolute event rates were 3.8% among treated women versus 0.5% in the comparison group. The finding, reported in regulatory and industry coverage in October 2026, raises safety questions about testosterone use in postmenopausal women. As an observational, retrospective analysis, it shows association rather than causation, and the biological mechanisms and generalizability of the result have not been established.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- Medical XpressPickTestosterone therapy may increase risk of cardiovascular disease in postmenopausal women
A Drexel University team used data from the TriNetX US Collaborative Network to conduct a retrospective cohort study of more than 6,300 propensity score-matched postmenopausal women. Testosterone therapy was associated with a significantly higher risk of composite cardiovascular disease (hazard ratio 8.08, 95% CI 4.72-13.82), with absolute event rates of 3.8% versus 0.5%.
Coverage and heat for this story
Reports so far 1·Heat now 6·Peak heat 10 (Oct 20 21:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.